IB 1001 (Inspiration BioPharm) is filed at FDA for Haemophilia B - 18-Apr-2012
Inspiration Biopharmaceuticals has submitted a biologics license application (BLA) to the FDA for the approval of IB1001, an intravenous recombinant factor IX for the treatment and prevention of bleeding in Haemophilia B. The product has been filed at EMA by Ipsen and launches are expected in Europe in late 2012 or early 2013 and in the USA in early 2013.
Related News
Phase III trial for N9-GP(Novo Nordisk) treatment for Haemophilia B
FDA accepts BLA from Biogen for Eloctate for treatment of Haemophilia A
Biogen IDEC files rFVIII Fc at FDA for treatment of Haemophilia A
FDA expands approval of Corifact (CSL Behring) to manage surgical bleeding in adult and pediatric patients with Factor XIII Deficiency
Successful studies for rFVIIIFc and rFIXFc (Biogen/Swedish Orphan) for Haemopilia
BAX 855 enters Phase II/III study for Haemophilia
Biogen Idec files rFIXFc at FDA for treatment of Haemophilia B
Phase III results for BAX 326 (Baxter) for Haemophilia B
Related Haematology Information
Haematology Clinical Guidelines
Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection
AidsinfoBritish HIV Association guidelines for the treatment of TB/HIV coinfection 2011
British HIV AssociationHaematology Clinical Trials
Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (DASAPOST)
Clinicaltrials.gov 27 February 2013A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of FG-4592 for the Treatment of Anemia in Chronic Kidney Disease Patients not on Dialysis
Clinical Trials Register.eu 05 February 2013Haematology Medical Journal Abstracts
PedsQL™ Sickle Cell Disease Module: Feasibility, Reliability, and Validity
Pediatric Blood & Cancer 25 February 2013Validation of Variants in SLC28A3 and UGT1A6 as Genetic Markers Predictive of Anthracycline-Induced Cardiotoxicity in Children
Pediatric Blood & Cancer 25 February 2013Haematology Medical Apps
The Oncologist
Free
ACP PIER Database - Hematology
£37.29
Related Haematology Drugs
- FENOFIBRATE 267MG CAPSULES
- FANHDI 25 I.U./ML, 50 I.U./ML AND 100 I.U./ML
- RIENSO 30 MG/ML SOLUTION FOR INJECTION
- GALFER CAPSULES
- TREDAPTIVE 1000 MG/20 MG MODIFIED RELEASE TABLETS
- FEOSPAN SPANSULE CAPSULES
- EPREX 2000, 4000 AND 10000 IU/ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
- FLUVASTATIN 40MG CAPSULES
- FLUVASTATIN 20MG CAPSULES
- HAEMONINE 500 / HAEMONINE 1000
- OCTANATE 50IU/ML
Advert for Healthcare Professionals only